UBX [NASD]
Unity Biotechnology, Inc.
Index- P/E- EPS (ttm)-1.08 Insider Own3.00% Shs Outstand67.53M Perf Week-7.03%
Market Cap55.02M Forward P/E- EPS next Y-1.20 Insider Trans0.00% Shs Float65.62M Perf Month-21.41%
Income-63.90M PEG- EPS next Q-0.28 Inst Own39.10% Short Float0.68% Perf Quarter-17.05%
Sales4.80M P/S11.46 EPS this Y41.00% Inst Trans-6.64% Short Ratio0.85 Perf Half Y-67.57%
Book/sh0.75 P/B1.02 EPS next Y-15.10% ROA-51.20% Target Price6.86 Perf Year-83.96%
Cash/sh1.10 P/C0.70 EPS next 5Y- ROE-109.20% 52W Range0.69 - 5.09 Perf YTD-47.81%
Dividend- P/FCF- EPS past 5Y-8.40% ROI-69.60% 52W High-85.01% Beta0.40
Dividend %- Quick Ratio4.60 Sales past 5Y- Gross Margin- 52W Low9.64% ATR0.07
Employees65 Current Ratio4.60 Sales Q/Q- Oper. Margin- RSI (14)38.67 Volatility7.65% 8.51%
OptionableYes Debt/Eq0.38 EPS Q/Q3.70% Profit Margin- Rel Volume0.33 Prev Close0.76
ShortableYes LT Debt/Eq0.29 Earnings- Payout- Avg Volume527.08K Price0.76
Recom1.70 SMA20-9.08% SMA50-23.56% SMA200-57.95% Volume171,918 Change0.21%
Jan-04-22Upgrade ROTH Capital Neutral → Buy
Nov-10-21Upgrade Mizuho Neutral → Buy $5 → $7
Jun-28-21Upgrade Citigroup Sell → Buy $6
Jun-07-21Initiated H.C. Wainwright Buy $12
Feb-16-21Downgrade Citigroup Neutral → Sell $5 → $6
Aug-18-20Downgrade Morgan Stanley Overweight → Equal-Weight $5
Aug-18-20Downgrade Mizuho Buy → Neutral $33 → $4
Aug-18-20Downgrade Citigroup Buy → Neutral $31 → $5
Aug-17-20Downgrade ROTH Capital Buy → Neutral
Jul-28-20Initiated ROTH Capital Buy $35
Dec-12-19Initiated Cantor Fitzgerald Overweight $20
Mar-07-19Initiated Cantor Fitzgerald Overweight $21
Sep-07-18Initiated Mizuho Buy
May-29-18Initiated Morgan Stanley Overweight $25
May-29-18Initiated Goldman Neutral $17
May-29-18Initiated Citigroup Buy $32
May-25-22 08:00AM  
May-10-22 04:00PM  
May-05-22 08:00AM  
Apr-21-22 08:00AM  
Apr-19-22 08:00AM  
Apr-12-22 08:00AM  
Mar-17-22 12:51PM  
Mar-15-22 08:00AM  
Mar-01-22 08:00AM  
Feb-14-22 08:00AM  
Feb-03-22 06:00PM  
04:01PM  
Feb-02-22 08:00AM  
Jan-25-22 05:38PM  
Jan-04-22 08:00AM  
Dec-22-21 08:00AM  
Dec-20-21 08:00AM  
Nov-10-21 12:35PM  
08:00AM  
Nov-09-21 07:00AM  
Nov-03-21 08:00AM  
Oct-06-21 08:00AM  
Oct-05-21 12:15PM  
07:00AM  
Oct-04-21 01:00AM  
Sep-07-21 04:00PM  
Aug-18-21 08:00AM  
Aug-16-21 04:03PM  
Aug-10-21 04:01PM  
Jul-28-21 07:40PM  
07:16PM  
08:00AM  
Jul-23-21 08:00AM  
Jul-06-21 08:59AM  
07:00AM  
Jun-18-21 03:03PM  
Jun-08-21 08:25AM  
Jun-02-21 08:00AM  
May-11-21 08:00AM  
May-01-21 07:00AM  
Apr-28-21 08:00AM  
Apr-21-21 08:00AM  
Mar-23-21 04:01PM  
Mar-11-21 04:05PM  
Mar-08-21 08:00AM  
Feb-26-21 04:05PM  
Feb-24-21 08:00AM  
Feb-08-21 08:00AM  
Feb-03-21 08:00AM  
Feb-01-21 08:00AM  
Jan-12-21 10:44AM  
Dec-22-20 07:45AM  
Dec-16-20 08:00AM  
Dec-14-20 07:00AM  
Dec-02-20 10:56AM  
Nov-04-20 04:01PM  
Oct-12-20 08:00AM  
Sep-15-20 08:00AM  
Sep-04-20 08:00AM  
Aug-31-20 04:05PM  
Aug-25-20 08:39AM  
Aug-18-20 09:21AM  
Aug-17-20 01:49PM  
11:32AM  
11:12AM  
07:00AM  
Aug-04-20 04:05PM  
Jul-31-20 07:57AM  
Jul-29-20 04:05PM  
Jul-24-20 08:00AM  
Jul-06-20 05:00PM  
Jul-02-20 08:21AM  
Jul-01-20 04:05PM  
Jun-11-20 02:32PM  
Jun-08-20 09:04AM  
Jun-05-20 01:11PM  
May-28-20 04:05PM  
May-07-20 04:05PM  
May-04-20 04:30PM  
Apr-27-20 11:06AM  
Apr-20-20 08:24AM  
Mar-31-20 04:05PM  
Mar-30-20 05:20PM  
Mar-11-20 04:05PM  
Mar-03-20 04:05PM  
Mar-02-20 04:30PM  
Feb-25-20 06:00AM  
Feb-24-20 04:05PM  
Jan-30-20 01:49PM  
Dec-22-19 05:09PM  
Nov-06-19 04:05PM  
Oct-31-19 02:14PM  
08:00AM  
Oct-24-19 08:00AM  
Oct-23-19 03:29PM  
08:00AM  
Sep-20-19 08:00AM  
Aug-27-19 08:00AM  
Aug-23-19 12:50PM  
Aug-22-19 10:09AM  
Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase II clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. It also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of age-related eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California.